Is screening for pancreatic cancer in high-risk groups cost-effective? - Experience from a Danish national screening program

With a threshold value of 50,000 US$ per QALY this screening program appears to constitute a cost-effective intervention although screening of HP patients appears to be less cost-effective than FPC patients.